Officials from Bavarian Nordic yesterday announced the results of a successful Phase 3 clinical trial led by USAMRIID that demonstrated the safety and efficacy of the company's investigational, ...

ATLANTA - March 11, 2026 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancer, today ...

Exercised options total USD 97 million, covering manufacturing of bulk vaccine and supply of freeze-dried vaccines. Company upgrades full-year financial guidance COPENHAGEN, Denmark, May 11, 2026 – ...

As India prepares to mark its 80th Independence Day on August 15, its pharmaceutical industry has quietly delivered a milestone, since 1947, that fits the occasion better than most. On May 30, 2026, ...

Often called the Speckled monster, Smallpox was one of the most terrifying diseases known to humanity. In 18th-century Europe alone, the disease killed an estimated 400,000 people every year, with a ...

GeoVax Labs, Inc. highlighted an important change in the U.S. epidemiology of Clade I mpox reported by the U.S. Centers for Disease Control and Prevention (CDC). GEO-MVA is GeoVax?s Modified Vaccinia ...

Sina Bavari, PhD, discusses promising preclinical findings for the investigational TNX-801 vaccine, emerging mpox variants, durable immunity, and why infection preventionists should continue preparing ...

An ad hoc committee of the National Academies of Sciences, Engineering, and Medicine will conduct a study to examine lessons learned from the recent Coronavirus Disease 2019 (COVID-19) pandemic and ...

Last fall, as the nation grappled with a spate of anthrax mailings that left five dead and contaminated parts of the postal system, government officials took extraordinary measures to defend against a ...